Functional immune responses against SARS-CoV-2 variants of concern after fourth COVID-19 vaccine dose or infection in patients with blood cancer.
Cell Rep Med
; 3(10): 100781, 2022 10 18.
Artículo
en Inglés
| MEDLINE | ID: covidwho-2042207
ABSTRACT
Patients with blood cancer continue to have a greater risk of inadequate immune responses following three COVID-19 vaccine doses and risk of severe COVID-19 disease. In the context of the CAPTURE study (NCT03226886), we report immune responses in 80 patients with blood cancer who received a fourth dose of BNT162b2. We measured neutralizing antibody titers (NAbTs) using a live virus microneutralization assay against wild-type (WT), Delta, and Omicron BA.1 and BA.2 and T cell responses against WT and Omicron BA.1 using an activation-induced marker (AIM) assay. The proportion of patients with detectable NAb titers and T cell responses after the fourth vaccine dose increased compared with that after the third vaccine dose. Patients who received B cell-depleting therapies within the 12 months before vaccination have the greatest risk of not having detectable NAbT. In addition, we report immune responses in 57 patients with breakthrough infections after vaccination.
Palabras clave
Texto completo:
Disponible
Colección:
Bases de datos internacionales
Base de datos:
MEDLINE
Asunto principal:
Vacunas contra la COVID-19
/
COVID-19
/
Neoplasias
Tipo de estudio:
Estudio pronóstico
Tópicos:
Vacunas
/
Variantes
Límite:
Humanos
Idioma:
Inglés
Revista:
Cell Rep Med
Año:
2022
Tipo del documento:
Artículo
País de afiliación:
J.xcrm.2022.100781
Similares
MEDLINE
...
LILACS
LIS